Intervacc (Q2 initial take): Few surprises – all eyes on the label extension - Redeye
Q2 contained few surprises, and the small absolute figures remain of limited importance to our estimates. Instead, we focus on the recently submitted label extension, which we regard as a key catalyst for Strangvac’s commercial adoption.
ANNONS
Q2 contained few surprises, and the small absolute figures remain of limited importance to our estimates. Instead, we focus on the recently submitted label extension, which we regard as a key catalyst for Strangvac’s commercial adoption.